Intuitive Surgical Is Down 28%, and Wall Street Is Piling On. Goldman Sachs Just Said Everyone Is Wrong -- and History Is on Its Side.

Intuitive Surgical Q1 revenue rose 23% YoY to $2.77B, with EPS up 18.7% to $2.28 and instruments/ accessories revenue segment growing 23% YoY to $1.69B. The company extended instrument lifetimes (force-feedback tools: 6 to 15 uses for 5 of 6 tools), which investors feared would hurt recurring revenue but Goldman argues it mainly eases supply constraints and should cause only a ~2% modeled-to-actual procedure revenue dip that later rebounded. Despite the defensive market reaction (ISRG down ~28% YTD) and multiple analyst downgrades with some price-target cuts, Goldman lifted its target to $558; key risk remains premium valuation (>49x trailing earnings) ahead of the July earnings report.

Analysis

The market is treating the instrument-lifetime change as a pure consumables haircut, but the more important mechanism is adoption elasticity: lower per-case operating cost can pull in hospitals that were marginal on utilization economics and expand procedure growth faster than it compresses revenue per procedure. That shifts the debate from “lost recurring revenue” to “faster installed-base monetization,” especially if higher-end tools keep mix richer than legacy accessories.

Competitive pressure is real, but the bigger second-order effect is on rival robotics platforms rather than refurbishers. If ISRG makes the economics of robotic surgery easier to justify, it can raise the bar for MDT’s Hugo and JNJ’s Ottava by forcing them to compete on clinical differentiation without a clear cost advantage. The risk is that a premium multiple leaves no cushion if management cannot show that the mix upgrade offsets any lower tool usage intensity.

Near term, the July print is the main catalyst; the next 1-3 months are about guidance credibility, while the 6-18 month story is whether cheaper procedures accelerate penetration in lower-acuity settings. The contrarian view is that the selloff may be overdone because a modest revenue-per-procedure drag can be more than offset by higher procedure volumes and faster system adoption. What would falsify that view is any guide implying a >2-3% structural hit to U.S. revenue per procedure or a slowdown in procedure growth.

Key Decisions for Investors

• Initiate a small tactical long ISRG on post-earnings weakness only if management reiterates that revenue-per-procedure impact remains low-single-digit; 6-12 month upside comes from multiple re-rating if growth holds.
• Pair trade: long ISRG / short MDT for a 1-3 month catalyst window, expressing confidence that ISRG’s cost-reset expands adoption faster than MDT can close the clinical gap.
• For existing ISRG longs, hedge into July earnings with a short-dated put spread or reduced gross exposure; the main risk is valuation compression on any guidance ambiguity, not a thesis break.
• Set a watch item on 2027 instrument commentary: if management gives clearer data that the mix shift is adoption-positive and not margin-destructive, add to ISRG; if not, take profits on rallies.